p53在调控DNA损伤所致MDAMB-231细胞死亡中的作用及其机制

doi:10.3969/j.issn.1004-616x.2018.05.004

Abstract

Abstract: OBJECTIVE:To investigate protective effect against cell death in DNA damage-induced breast 2 cancer cell line MDA-MB-231. METHODS:MDA-MB-231 cells were irradiated with 5 J/m² UVC and were used to establish our DNA damage cell model. Western blot was used to detect DNA damage marker phospho-H2AX;cell death related proteins:p53, p21, and PARP; and nuclear factor NF-90 which regulates p53 and p21 expression. 2 RESULTS:At 0.5 h after 5 J/m² UVC irradiation of MDA-MB-231 cells,phospho-H2AX expression was induced (P < 0.05),p21 was degraded (P < 0.05),and phosphor-p53 (p-p53) was induced (P < 0.05). At 8 hours after irradiation, PARP was cleaved (P < 0.05). There were not any significant changes on p53 and NF-90. CONCLUSION:From our cell model of DNA damage in MDA-MB-231 cell line,p21-PARP pathway was involved in induction of cell death,but phosphor-p53 was resistant. These imply that phosphor-p53 showed a protective role on this model.

Key words: breast cancer, DNA damage, cell death, p53, p21

CLC Number:

R737.9

JIANG Pengtao, HU Zhifang, GAO Xingchun, GUO Na, ZHANG Dian, JIANG Fengliang. Involvement of p53 in regulation of DNA damage-induced cell death in MDA-MB-231[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(5): 349-353.

References

[1] TORRE L A,BRAY F,SIEGEL R L,et al. Global cancer statistics,2012[J]. CA Cancer J Clin,2015,65(2):87-108.
[2] CHEN W,ZHENG R,BAADE P D,et al. Cancer statistics in China,2015[J]. CA Cancer J Clin,2016,66(2):115-132.
[3] HARRIS R S. Molecular mechanism and clinical impact of APOBEC3B-catalyzed mutagenesis in breast cancer[J]. Breast Cancer Res,2015,17:8.
[4] ALI R,RAKHA E A,MADHUSUDAN S,et al. DNA damage repair in breast cancer and its therapeutic implications[J].Pathology,2017,49(2):156-165.
[5] SHARMA A, SINGH K, ALMASAN A. Histone H2AX phosphorylation:a marker for DNA damage[J]. Methods Mol Biol,2012,920:613-626.
[6] SCHINDELIN J,ARGANDA-CARRERAS I,FRISE E,et al. Fiji:an open-source platform for biological-image analysis[J]. Nat Methods,2012,9(7):676-682.
[7] JUNG Y S,QIAN Y,CHEN X. Examination of the expanding pathways for the regulation of p21 expression and activity[J]. Cell Signal,2010,22(7):1003-1012.
[8] SHAMANNA R A,HOQUE M,PE'ERY T,et al. Induction of p53,p21 and apoptosis by silencing the NF90/NF45 complex in human papilloma virus-transformed cervical carcinoma cells[J]. Oncogene,2013,32(43):5176-5185.
[9] CONCONI A,BELL B. Molecular biology:The long and short of a DNA-damage response[J]. Nature, 2017, 545(7653):165-166.
[10] DAPIC V,CARVALHO M A,MONTEIRO A N. Breast cancer susceptibility and the DNA damage response[J]. Cancer Control,2005,12(2):127-136.
[11] SHEIKH M S, CHEN Y Q, SMITH M L, et al. Role of p21Waf1/Cip1/Sdi1 in cell death and DNA repair as studied using a tetracycline-inducible system in p53-deficient cells[J]. Oncogene,1997,14(15):1875-1882.
[12] ABBAS T, SIVAPRASAD U, TERAI K, et al. PCNA-dependent regulation of p21 ubiquitylation and degradation via the CRL4Cdt2 ubiquitin ligase complex[J]. Genes Dev,2008, 22(18):2496-2506.
[13] GARTEL A L,TYNER A L. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis[J]. Mol Cancer Ther,2002, 1(8):639-649.
[14] GEORGAKILAS A G,MARTIN O A,BONNER W M. p21:A two-faced genome guardian[J]. Trends Mol Med, 2017, 23(4):310-319.
[15] FENG C, YANG M, ZHANG Y, et al. Cyclic mechanical tension reinforces DNA damage and activates the p53-p21-Rb pathway to induce premature senescence of nucleus pulposus cells[J]. Int J Mol Med,2018,41(6):3316-3326.
[16] ZHU K, LIU Q, ZHOU Y, et al. Oncogenes and tumor suppressor genes:comparative genomics and network perspectives[J]. BMC Genomics,2015,16(Sup 7):8.
[17] LEVINE A J. p53, the cellular gatekeeper for growth and division[J]. Cell,1997,88(3):323-331.
[18] GASCO M,SHAMI S,CROOK T. The p53 pathway in breast cancer[J]. Breast Cancer Res,2002,4(2):70-76.
[19] GOMES A S,TROVAO F,ANDRADE PINHEIRO B,et al. The crystal structure of the R280K mutant of human p53 explains the loss of DNA binding[J]. Int J Mol Sci,2018, 19(4):1184.
[20] YI X, HONG M, GUI B, et al. RNA processing and modification protein,carbon catabolite repression 4(Ccr4), arrests the cell cycle through p21-dependent and p53-independent pathway[J]. J Biol Chem,2012,287(25):21045-21057.
[21] MATEO J,DE BONO J S. Targeting DNA damage response systems to impact cancer care[J]. Curr Probl Cancer,2017, 41(4):247-250.

Involvement of p53 in regulation of DNA damage-induced cell death in MDA-MB-231

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	XIN Yumeng, LIANG Huanxi, YU Yuehua, SUN Zhenxiao. Network pharmacology and molecular docking mechanisms of licorice and dried ginger decoction against breast cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 7-13.
[2]	ZHAO Yan, SUN Zhenxiao. Metformin inhibitd proliferation and migration of human breast cancer cell in vitro [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 35-39.
[3]	FANG Yutong, ZHANG Qunchen, HONG Chaoqun, CHEN Chunfa, CHEN Jiongyu, ZHANG Rendong, WU Jundong. Mechanisms of miR-221 and miR-222 on expression of GATA3 and FOXA1 and their effects in breast cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 435-441,460.
[4]	ZHANG Shimin, ZHAO Ruijun. Expression of protein tyrosine phosphatase receptor J in breast cancer tissues and its relationship with clinical prognosis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 276-279,285.
[5]	HUANG Xiaohua, NIU Yongdong, SHI Ganggang. Inhibitory effects and mechanisms of nuclear receptor FXR activation in cervical cancer cell line CaSki [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 302-306.
[6]	CHENG Bin, WANG Xinyu, SUN Yu, ZHANG Jiatai, DONG Shuying. Inhibition of metformin on phthalate-induced proliferation and migration of MCF-7 breast cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 197-202.
[7]	LUO Jiao, ZHANG Kunchi, ZHOU Li. Analysis of differentially expressed microRNAs between the triple negative breast cancer cell line MDA-MB-231 and its brain metastasis cell line [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 218-224.
[8]	WANG Yaokun, CHEN Juexiao, ZHANG Mingyuan, SHAO Changli, YANG Yu, SHANG Yu. Database analysis of genome variations and targeted drug screening of anaplastic thyroid cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(1): 53-57.
[9]	LI Weiwei, ZHU Ying. Data mining analyses of expression and prognostic values of the MYB family in breast cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 414-422.
[10]	CHEN Mianling, MA Shuoyi. Regulation of migration and invasion of triple-negative breast cancer cell MDA-MB-231 by miR-21 via targeting PDCD4 [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(4): 292-297.
[11]	ZHANG Huijuan, HUANG Dayuan, ZHANG Jie, TANG Haiou, XIE Anxin, TAN Dunyong. Effects of SF1a-PRLR and ΔS2 SF1a-PRLR on proliferation and microRNA expressionin MCF-7 breast cancer cell [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(3): 203-208.
[12]	ZHOU Changhui, HAN Tianjiao, HUANG Pengcheng, MA Jing, CHANG Yan. Validation study of comet assay in multiple organs of rats [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(3): 233-237.
[13]	WANG Bingyu, ZHENG Kai, XU Xinyun, XIE Hongwei, YU Junhui, LONG Dingxin. PM_2.5 on DNA damage in human bronchial epithelial cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(6): 469-473,497.
[14]	SUN Quanwu, DU Xiaoping, HAO Jie, SHI Rong, LIU Bo, HUANG Haiyun. β1 integrin expression in breast cancer patients with pathological nipple discharge [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(5): 368-372.
[15]	WANG Lan, ZHANG Yongdong, GUO Hongyun, WANG Tao, WANG Haitao, GUO Huan, YANG Suisheng, LI Xiaoqin, SU Haixiang. Relationships between XRCC3 polymorphisms and breast cancer in northern Chinese women [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(5): 392-396,400.